The observation was counter-screened by co-delivering PD-L1 blockade with paclitaxel (alone being an HMGA2 upregulation and concomitant stimulation of CXCL10/CXCL11), revealing a decreased tumor growth compared to singular treatment with a PD-L1 inhibitor, in the KRAS-G12D-mutant LUAD carrying mouse model. This evidence concerns the gene KRAS and neoplasm.